Analyst Expectations for Ascendis Pharma's Future
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 7 analysts have published their opinion on Ascendis Pharma (NASDAQ:ASND) stock, with 5 being somewhat bullish and 2 indifferent. The average 12-month price target for Ascendis Pharma is $150.14, which has increased by 9.59% over the past month.
November 09, 2023 | 2:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Analysts are somewhat bullish on Ascendis Pharma with an average 12-month price target of $150.14, which has increased by 9.59% over the past month.
The stock is expected to perform well in the short term as the average price target has increased by 9.59% over the past month. This indicates that analysts are optimistic about the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100